Non-osteoporotic post-menopausal women do not have elevated concentrations of autoantibodies against osteoprotegerin

Isabelle Piec, Sophie Paddock, Christopher Washbourne, Jonathan Tang, Julie Greeves, Sarah Jackson, Stuart Ralston, Philip Riches, Helen McDonald, William Fraser

Research output: Contribution to conferencePoster

8 Downloads (Pure)

Abstract

Introduction:
Osteoprotegerin (OPG) plays a protective role in bone remodelling as it provides a ‘decoy’ binding site for RANKL, preventing the stimulation of osteoclasts. Autoantibodies to OPG allow a sustained reaction between RANKL and RANK which in turn increase bone degradation. Autoantibodies against Osteoprotegerin (-OPGAb) first isolated in patients with autoimmune conditions associated with high bone turnover have been shown to be present in 14% of a healthy young adult population. Bone degradation is more prominent in the oldest population, particularly in women.
Objective:
To define a reference range for OPG autoantibodies in non-osteoporotic post-menopausal women.
Method:
Using a previously developed sandwich ELISA assay we were able to detect OPG autoantibody in serum samples taken from non-osteoporotic post-menopausal women (ANSAVID study - 60-65yrs). Briefly, -OPGAb are captured by the use of an immobilized full-length human recombinant OPG and detected by the sequential addition of a biotinylated antibody and a horseradish-peroxidase-labelled streptavidin. The concentration of human α-OPGAb in the samples is determined directly from a 4PL-fit standard curve.
Results:
We established that the population of post-menopausal women who do not present osteoporosis do not have elevated concentration of -OPGAb as compared to a younger healthy population (17-32yrs). This suggest that -OPGAb is not normally occurring with age suggesting that the production of -OPGAb is solely related to pathologic conditions in which the bone is heavily degraded.
Conclusion:
Comparison of osteoporotic patient samples to the non-osteoporotic post-menopausal women would be interesting to determine whether -OPGAb can be used to identify appropriate treatment options for this particular subgroup of patients.
Original languageEnglish
Publication statusPublished - 8 Oct 2015
EventAmerican Society for Bone and Mineral Research - Seattle, United States
Duration: 7 Oct 201512 Oct 2015

Conference

ConferenceAmerican Society for Bone and Mineral Research
CountryUnited States
CitySeattle
Period7/10/1512/10/15

Cite this